Salivary Gland Hypofunction and Xerostomia in Head and Neck Radiation Patients

2019 ◽  
Vol 2019 (53) ◽  
Author(s):  
Siri Beier Jensen ◽  
Arjan Vissink ◽  
Kirsten H Limesand ◽  
Mary E Reyland

AbstractBackgroundThe most manifest long-term consequences of radiation therapy in the head and neck cancer patient are salivary gland hypofunction and a sensation of oral dryness (xerostomia).MethodsThis critical review addresses the consequences of radiation injury to salivary gland tissue, the clinical management of salivary gland hypofunction and xerostomia, and current and potential strategies to prevent or reduce radiation injury to salivary gland tissue or restore the function of radiation-injured salivary gland tissue.ResultsSalivary gland hypofunction and xerostomia have severe implications for oral functioning, maintenance of oral and general health, and quality of life. Significant progress has been made to spare salivary gland function chiefly due to advances in radiation techniques. Other strategies have also been developed, e.g., radioprotectors, identification and preservation/expansion of salivary stem cells by stimulation with cholinergic muscarinic agonists, and application of new lubricating or stimulatory agents, surgical transfer of submandibular glands, and acupuncture.ConclusionMany advances to manage salivary gland hypofunction and xerostomia induced by radiation therapy still only offer partial protection since they are often of short duration, lack the protective effects of saliva, or potentially have significant adverse effects. Intensity-modulated radiation therapy (IMRT), and its next step, proton therapy, have the greatest potential as a management strategy for permanently preserving salivary gland function in head and neck cancer patients.Presently, gene transfer to supplement fluid formation and stem cell transfer to increase the regenerative potential in radiation-damaged salivary glands are promising approaches for regaining function and/or regeneration of radiation-damaged salivary gland tissue.

2021 ◽  
pp. JCO.21.01208
Author(s):  
Valeria Mercadante ◽  
Siri Beier Jensen ◽  
Derek K. Smith ◽  
Kari Bohlke ◽  
Jessica Bauman ◽  
...  

PURPOSE To provide evidence-based recommendations for prevention and management of salivary gland hypofunction and xerostomia induced by nonsurgical cancer therapies. METHODS Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials published between January 2009 and June 2020. The guideline also incorporated two previous systematic reviews conducted by MASCC/ISOO, which included studies published from 1990 through 2008. RESULTS A total of 58 publications were identified: 46 addressed preventive interventions and 12 addressed therapeutic interventions. A majority of the evidence focused on the setting of radiation therapy for head and neck cancer. For the prevention of salivary gland hypofunction and/or xerostomia in patients with head and neck cancer, there is high-quality evidence for tissue-sparing radiation modalities. Evidence is weaker or insufficient for other interventions. For the management of salivary gland hypofunction and/or xerostomia, intermediate-quality evidence supports the use of topical mucosal lubricants, saliva substitutes, and agents that stimulate the salivary reflex. RECOMMENDATIONS For patients who receive radiation therapy for head and neck cancer, tissue-sparing radiation modalities should be used when possible to reduce the risk of salivary gland hypofunction and xerostomia. Other risk-reducing interventions that may be offered during radiation therapy for head and neck cancer include bethanechol and acupuncture. For patients who develop salivary gland hypofunction and/or xerostomia, interventions include topical mucosal lubricants, saliva substitutes, and sugar-free lozenges or chewing gum. For patients with head and neck cancer, oral pilocarpine and oral cevimeline, acupuncture, or transcutaneous electrostimulation may be offered after radiation therapy. Additional information can be found at www.asco.org/supportive-care-guidelines .


2004 ◽  
Vol 73 (3) ◽  
pp. 289-296 ◽  
Author(s):  
Simon Buus ◽  
Cai Grau ◽  
Ole Lajord Munk ◽  
Dirk Bender ◽  
Kenneth Jensen ◽  
...  

Oral Oncology ◽  
2010 ◽  
Vol 46 (5) ◽  
pp. 349-354 ◽  
Author(s):  
G.C. Jaguar ◽  
E.N.P. Lima ◽  
L.P. Kowalski ◽  
A.C. Pellizon ◽  
A.L. Carvalho ◽  
...  

2005 ◽  
Vol 74 (3) ◽  
pp. 251-258 ◽  
Author(s):  
Kauko Saarilahti ◽  
Mauri Kouri ◽  
Juhani Collan ◽  
Tuomo Hämäläinen ◽  
Timo Atula ◽  
...  

2012 ◽  
Vol 103 ◽  
pp. S64 ◽  
Author(s):  
P. van Luijk ◽  
S. Pringle ◽  
J.O. Deasy ◽  
V.V. Moiseenko ◽  
H. Faber ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document